ULTRAGENYX PHARMACEUTICAL INC. (NASDAQ:RARE) Files An 8-K Completion of Acquisition or Disposition of AssetsItem 2.01
|
Exhibit No. |
Description |
| 23.1 | Consent of PricewaterhouseCoopers LLP, independent registered public accounting firm |
| 99.1 | Press Release of Ultragenyx Pharmaceutical Inc., dated November7, 2017 |
| 99.2 | Unaudited consolidated financial statements of Dimension as of September30, 2017 and for the nine months ended September 30, 2017 and 2016, together with the notes thereto (incorporated herein by reference from pages 1 through 15 of Dimension’s Quarterly Report on Form 10-Q for the period ended September 30, 2017 (SEC File No.001-37601), filed with the SEC on November6, 2017). |
| 99.3 | Audited consolidated financial statements of Dimension as of December31, 2016 and for the year ended December 31, 2016, together with the notes thereto and the report of the independent registered public accounting firm thereon (incorporated herein by reference from pages F-1through F-28 of Dimension’s Annual Report on Form 10-K for the year ended December31, 2016 (SEC File No.001-37601), filed with the SEC on March9, 2017). |
** *
Ultragenyx Pharmaceutical Inc. ExhibitEX-23.1 2 d471778dex231.htm EX-23.1 EX-23.1 Exhibit 23.1 CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We hereby consent to the incorporation by reference in the Registration Statement on Form S-3 (No. 333-201838) and the Registration Statements on Form S-8 (No. 333-194773,…To view the full exhibit click here
About ULTRAGENYX PHARMACEUTICAL INC. (NASDAQ:RARE)
Ultragenyx Pharmaceutical Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the identification, acquisition, development, and commercialization of products for the treatment of genetic diseases. The Company is engaged in the identification, acquisition, development and commercialization of products for the treatment of rare and ultra-rare diseases segment. Its pipeline consists of two product categories: biologics, including a monoclonal antibody and enzyme replacement therapies, and small-molecule substrate replacement therapies. KRN23 is a fully human monoclonal antibody administered via subcutaneous injection. Recombinant human beta-glucuronidase (rhGUS), is an intravenous (IV), enzyme replacement therapy for the treatment of mucopolysaccharidosis 7 (MPS 7). It is developing UX007 for oral administration intended as a substrate replacement therapy. It is developing aceneuramic acid extended-release (Ace-ER) for the treatment of GNE myopathy.
